Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Biocon Limited ( (IN:BIOCON) ).
Biocon Biologics has announced a settlement agreement with Amgen Inc., paving the way for the commercialization of its Denosumab biosimilars, Vevzuo® and Evfraxy®, in Europe and other international markets starting December 2, 2025. This strategic move follows a similar settlement in the U.S. and is expected to enhance Biocon’s global reach in the oncology and bone health sectors, providing patients with more affordable treatment options. The European Commission had already approved these biosimilars in July 2025, marking a significant step in Biocon’s mission to expand its footprint in the global biosimilars market.
More about Biocon Limited
Biocon Limited is a global biosimilars company known for its focus on oncology and bone health therapeutic areas. As a subsidiary of Biocon Ltd., Biocon Biologics Ltd. is involved in developing and commercializing biosimilars, with a strong emphasis on expanding access to affordable biologics worldwide.
Average Trading Volume: 123,220
Technical Sentiment Signal: Strong Buy
Current Market Cap: 531.4B INR
Find detailed analytics on BIOCON stock on TipRanks’ Stock Analysis page.